Atom | Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

Due Dates: April 5, 2025 (Renewal/Resubmission/Revision) | September 5, 2025 (New & Renewal/Resubmission/Revision)

Funding Amounts: Phase I: up to $500,000 (2 years); Phase II: up to $2.5M (3 years) for AD/ADRD topics (with SBA waiver); typical ceiling $1,838,436 for Phase II

Summary: Supports small business-led research to develop innovative products, services, or technologies for the prevention, diagnosis, treatment, or care of Alzheimer's disease and related dementias.

Key Information: Updated March 2025: Align proposals with current NIH priorities; see full FOA for new requirements and foreign disclosure rules.

Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

Sign in to see full grant listing